Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving Hydroxychloroquine or Favipiravir
Alosaimi et al., Pharmaceuticals, doi:10.3390/ph15121456
https://c19hcq.org/alosaimi.html